Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · INOmax
INOmax 400 ppm mol/mol medicinal gas, compressed · Abschnitt 4.5 · PDF-Seite 6
HOS-108515 · Präparat HOS-093033
No interaction studies have been performed.
A clinically significant interaction with other medicinal products used in the treatment of hypoxic
respiratory failure cannot be excluded based on the available data. There may be an additive effect
with INOmax on the risk of developing methaemoglobinemia with nitric oxide donor substances,
including sodium nitroprusside and nitroglycerin. INOmax has been safely administered with
tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sodium nitroprusside (HOS-108516) dopamine (HOS-085948) dobutamine (HOS-086565) tolazoline (HOS-108518) nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T11:01:00Z · SHA-256 4c3ecbe485d3d0d3f3d8a8b72af806e039310534c247a674f80a0286630fc6f8 · Passage dab7a389668e50d053c9d3555bd8c0eab012fc25696c5b28f1962aef58f4ba2e · Zeichen 0–600 im Abschnitt
Wechselwirkungen · INOmax
INOmax 800 ppm mol/mol medicinal gas, compressed · Abschnitt 4.5 · PDF-Seite 18
HOS-108537 · Präparat HOS-093033
No interaction studies have been performed.
A clinically significant interaction with other medicinal products used in the treatment of hypoxic
respiratory failure cannot be excluded based on the available data. There may be an additive effect
with INOmax on the risk of developing methaemoglobinemia with nitric oxide donor substances,
including sodium nitroprusside and nitroglycerin. INOmax has been safely administered with
tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sodium nitroprusside (HOS-108516) dopamine (HOS-085948) dobutamine (HOS-086565) tolazoline (HOS-108518) nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T11:01:00Z · SHA-256 4c3ecbe485d3d0d3f3d8a8b72af806e039310534c247a674f80a0286630fc6f8 · Passage dab7a389668e50d053c9d3555bd8c0eab012fc25696c5b28f1962aef58f4ba2e · Zeichen 0–600 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111253 · Präparat HOS-093485
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of CIALIS to patients who are using any form of organic nitrate is
contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of CIALIS (2.5 mg-20 mg),
where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48
hours should have elapsed after the last dose of CIALIS before nitrate administration is considered. In
such circumstances, nitrates should only be administered under close medical supervision with
appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage fc4db7d2039b97ad74293b79ae923fd512afcec3aa283ef893465eb3c1ba77d7 · Zeichen 1992–2941 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-111301 · Präparat HOS-093485
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of CIALIS to patients who are using any form of organic nitrate is
contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of CIALIS (2.5 mg-20 mg),
where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48
hours should have elapsed after the last dose of CIALIS before nitrate administration is considered. In
such circumstances, nitrates should only be administered under close medical supervision with
appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage fc4db7d2039b97ad74293b79ae923fd512afcec3aa283ef893465eb3c1ba77d7 · Zeichen 1937–2886 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111340 · Präparat HOS-093485
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of CIALIS to patients who are using any form of organic nitrate is
contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of CIALIS (2.5 mg –
20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at
least 48 hours should have elapsed after the last dose of CIALIS before nitrate administration is
considered. In such circumstances, nitrates should only be administered under close medical
supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 6929febe16ec215455adb3640d688cfa0320adadc008cddc9beaf374671c4126 · Zeichen 1993–2944 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111598 · Präparat HOS-093557
In vivo studies
No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) was observed
when vardenafil (10 mg) was given at varying time intervals (1 h to 24 h) prior to the dose of
nitroglycerin in a study in 18 healthy male subjects. Vardenafil 20 mg film-coated tablets potentiated the
blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after vardenafil
administration to healthy middle aged subjects. No effect on blood pressure was observed when
nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg film-coated
tablets. However, there is no information on the possible potentiation of the hypotensive effects of
nitrates by vardenafil in patients, and concomitant use is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 726aebcb540eea8d5974e7bc7534863f009106c51b9bf4531ef805f9bc555e1d · Zeichen 3672–4500 im Abschnitt
Wechselwirkungen · Levitra
Levitra 10 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-111640 · Präparat HOS-093557
In vivo studies
No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) was observed
when vardenafil (10 mg) was given at varying time intervals (1 h to 24 h) prior to the dose of
nitroglycerin in a study in 18 healthy male subjects. Vardenafil 20 mg film-coated tablets potentiated the
blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after vardenafil
administration to healthy middle aged subjects. No effect on blood pressure was observed when
nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg film-coated
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 39b5121026e4056224954af20fefda3a9ec388f2eab9a2ee449def3800bff482 · Zeichen 3672–4295 im Abschnitt
Wechselwirkungen · Adempas
Adempas 0.5 mg film-coated tablets Adempas 1 mg film-coated tablets Adempas 1.5 mg film-coated tablets Adempas 2 mg film-coated tablets Adempas 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129028 · Präparat HOS-096659
Nitrates
In a clinical study the highest dose of riociguat (2.5 mg tablets 3 times daily) potentiated the blood
pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 4 and 8 hours after intake.
Therefore co-administration of riociguat with nitrates or nitric oxide donors (such as amyl nitrite) in
any form, including recreational drugs called ‘poppers’, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitric oxide (HOS-088773) nitroglycerin (HOS-108517) amyl nitrite (HOS-088775)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T01:00:00Z · SHA-256 3d1a5306a1e99b336747bac1f508fcb4f4b6128739940b8414bff8db32c20c38 · Passage 56d10bb505ac25f5710b503ce0ad8ac6b778aba6f400a674498c2baea7680a6d · Zeichen 367–773 im Abschnitt
Wechselwirkungen · Adempas
Adempas 0.15 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-129072 · Präparat HOS-096659
Nitrates
In a clinical study the highest dose of riociguat (2.5 mg tablets 3 times daily) potentiated the blood
pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 4 and 8 hours after intake.
Therefore co-administration of riociguat with nitrates or nitric oxide donors (such as amyl nitrite) in
any form, including recreational drugs called ‘poppers’, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitric oxide (HOS-088773) nitroglycerin (HOS-108517) amyl nitrite (HOS-088775)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T01:00:00Z · SHA-256 3d1a5306a1e99b336747bac1f508fcb4f4b6128739940b8414bff8db32c20c38 · Passage 56d10bb505ac25f5710b503ce0ad8ac6b778aba6f400a674498c2baea7680a6d · Zeichen 309–715 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-131382 · Präparat HOS-097067
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of nitrates.
Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated
(see section 4.3). Based on the results of a clinical study in which 150 subjects receiving daily doses of
tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for
more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose.
Thus, in a patient prescribed any dose of tadalafil (2.5 mg-20 mg), where nitrate administration is deemed
medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of
tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be
administered under close medical supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage 027e12c9558940969ed08744f20d5eb0ece6861b591a61d512960e61dec74957 · Zeichen 1994–2952 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-131431 · Präparat HOS-097067
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of nitrates.
Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated
(see section 4.3). Based on the results of a clinical study in which 150 subjects receiving daily doses of
tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for
more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose.
Thus, in a patient prescribed any dose of tadalafil (2.5 mg-20 mg), where nitrate administration is deemed
medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of
tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be
administered under close medical supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage 027e12c9558940969ed08744f20d5eb0ece6861b591a61d512960e61dec74957 · Zeichen 1934–2892 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 10 mg film-coated tablets Tadalafil Mylan 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131477 · Präparat HOS-097067
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of nitrates.
Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated
(see section 4.3). Based on the results of a clinical study in which 150 subjects receiving daily doses of
tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for
more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose.
Thus, in a patient prescribed any dose of tadalafil (2.5 mg-20 mg), where nitrate administration is deemed
medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of
tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be
administered under close medical supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage 027e12c9558940969ed08744f20d5eb0ece6861b591a61d512960e61dec74957 · Zeichen 1992–2950 im Abschnitt
Wechselwirkungen · Entresto
Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-134376 · Präparat HOS-097566
Nitrates, e.g. nitroglycerine
There was no interaction between sacubitril/valsartan and intravenously administered nitroglycerin
with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan
was associated with a treatment difference of 5 bpm in heart rate compared to the administration of
nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-
administered with sublingual, oral or transdermal nitrates. In general no dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T10:33:00Z · SHA-256 63effd0dd78bf1b11f8cfe5ae77efc68b2653de13ba467bbf4e48289e340b97e · Passage 5ed37fbf89dd032ebd7888248a35e4c522cf206f8784abdf328f49478341ac01 · Zeichen 4365–4897 im Abschnitt
Wechselwirkungen · Entresto
Entresto 6 mg/6 mg granules in capsules for opening Entresto 15 mg/16 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 29
HOS-134415 · Präparat HOS-097566
Nitrates, e.g. nitroglycerine
There was no interaction between sacubitril/valsartan and intravenously administered nitroglycerin
with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan
was associated with a treatment difference of 5 bpm in heart rate compared to the administration of
nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-
administered with sublingual, oral or transdermal nitrates. In general no dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T10:33:00Z · SHA-256 63effd0dd78bf1b11f8cfe5ae77efc68b2653de13ba467bbf4e48289e340b97e · Passage 5ed37fbf89dd032ebd7888248a35e4c522cf206f8784abdf328f49478341ac01 · Zeichen 4309–4841 im Abschnitt
Wechselwirkungen · Neparvis
Neparvis 24 mg/26 mg film-coated tablets Neparvis 49 mg/51 mg film-coated tablets Neparvis 97 mg/103 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-138100 · Präparat HOS-098142
Nitrates, e.g. nitroglycerine
There was no interaction between sacubitril/valsartan and intravenously administered nitroglycerin
with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan
was associated with a treatment difference of 5 bpm in heart rate compared to the administration of
nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-
administered with sublingual, oral or transdermal nitrates. In general no dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T16:33:00Z · SHA-256 08c9e21821039ca07b73a73e3ade3e3cdcfc16fa2da815f0f3e25e38fa083f2e · Passage 5ed37fbf89dd032ebd7888248a35e4c522cf206f8784abdf328f49478341ac01 · Zeichen 4366–4898 im Abschnitt
Wechselwirkungen · Neparvis
Neparvis 6 mg/6 mg granules in capsules for opening Neparvis 15 mg/16 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 28
HOS-138135 · Präparat HOS-098142
Nitrates, e.g. nitroglycerine
There was no interaction between sacubitril/valsartan and intravenously administered nitroglycerin
with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan
was associated with a treatment difference of 5 bpm in heart rate compared to the administration of
nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-
administered with sublingual, oral or transdermal nitrates. In general no dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T16:33:00Z · SHA-256 08c9e21821039ca07b73a73e3ade3e3cdcfc16fa2da815f0f3e25e38fa083f2e · Passage 5ed37fbf89dd032ebd7888248a35e4c522cf206f8784abdf328f49478341ac01 · Zeichen 4309–4841 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-140424 · Präparat HOS-098526
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of Tadalafil Lilly to patients who are using any form of organic
nitrate is contraindicated (see section 4.3). Based on the results of a clinical trial in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of Tadalafil Lilly
(2.5 mg - 20 mg), where nitrate administration is deemed medically necessary in a life-threatening
situation, at least 48 hours should have elapsed after the last dose of Tadalafil Lilly before nitrate
administration is considered. In such circumstances, nitrates should only be administered under close
medical supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage 9e1935073d116d8fd3797578b0a3f3599020b22d6c97aff973eb94025e895b39 · Zeichen 2008–2986 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-140481 · Präparat HOS-098526
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of Tadalafil Lilly to patients who are using any form of organic
nitrate is contraindicated (see section 4.3). Based on the results of a clinical trial in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of Tadalafil Lilly
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage 8d6e326928b0279c95a4acbd3af15540b406bff642e4d4977da6b3d2e69a5f39 · Zeichen 1951–2563 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 10 mg film-coated tablets Tadalafil Lilly 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-140524 · Präparat HOS-098526
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. Therefore, administration of Tadalafil Lilly to patients who are using any form of organic
nitrate is contraindicated (see section 4.3). Based on the results of a clinical trial in which 150 subjects
receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various
times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had
elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of Tadalafil Lilly
(2.5 mg - 20 mg), where nitrate administration is deemed medically necessary in a life-threatening
situation, at least 48 hours should have elapsed after the last dose of Tadalafil Lilly before nitrate
administration is considered. In such circumstances, nitrates should only be administered under close
medical supervision with appropriate haemodynamic monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage 9e1935073d116d8fd3797578b0a3f3599020b22d6c97aff973eb94025e895b39 · Zeichen 2007–2985 im Abschnitt
Wechselwirkungen · Yuvanci
Yuvanci 10 mg/20 mg film-coated tablets Yuvanci 10 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-143957 · Präparat HOS-099076
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of
nitrates. This interaction lasted for more than 24 hours and was no longer detectable when 48 hours
had elapsed after the last tadalafil dose. Therefore, administration of Yuvanci to patients who are using
any form of organic nitrate, such as nitroglycerin, isosorbide and amyl nitrate, is contraindicated (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isosorbide (HOS-143958) nitroglycerin (HOS-108517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T14:05:00Z · SHA-256 a85c92c510da73754302b7d31e905f6fb367473ebb25641258c217ee1f43268d · Passage 7909aad60b2b2f856b3374c780332942dcd78e9ab47eb818680781388c3a15ed · Zeichen 5129–5550 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.